Robust method for TALEN-edited correction of pF508del in patient-specific induced pluripotent stem cells by María Vicenta Camarasa & Víctor Miguel Gálvez
METHOD Open Access
Robust method for TALEN-edited correction
of pF508del in patient-specific induced
pluripotent stem cells
María Vicenta Camarasa* and Víctor Miguel Gálvez
Abstract
Cystic fibrosis is one of the most frequent inherited rare diseases, caused by mutations in the cystic fibrosis
transmembrane conductance regulator gene. Apart from symptomatic treatments, therapeutic protocols for
curing the disease have not yet been established. The regeneration of genetically corrected, disease-free epithelia in
cystic fibrosis patients is envisioned by designing a stem cell/genetic therapy in which patient-derived pluripotent stem
cells are genetically corrected, from which target tissues are derived. In this framework, we present an efficient method
for seamless correction of pF508del mutation in patient-specific induced pluripotent stem cells by gene edited
homologous recombination. Gene edition has been performed by transcription activator-like effector nucleases and
a homologous recombination donor vector which contains a PiggyBac transposon-based double selectable marker
cassette.
This new method has been designed to partially avoid xenobiotics from the culture system, improve cell culture
efficiency and genome stability by using a robust culture system method, and optimize timings. Overall, once the
pluripotent cells have been amplified for the first nucleofection, the procedure can be completed in 69 days, and
can be easily adapted to edit and change any gene of interest.
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Introduction
Genetic correction by homologous recombination (HR)
had proven extremely inefficient in human embryonic
stem (hES) or human induced pluripotent stem (hIPS)
cells before the advent of genome editing [1] and the
addition of ROCK (Rho-associated, coiled-coil-containing
protein kinase) inhibitor to cell dissociation steps [2].
Gene editing technologies have evolved quickly during
the past 10 years. Correction of monogenic disorders in
patient-specific induced pluripotent stem (iPS) cells is
feasible nowadays with the aid of gene editing tools re-
cently developed in several laboratories worldwide [3].
Efficiencies of homologous recombination increased
100-fold with the addition of engineered nucleases to
edit the gene of interest [4], although the need for intro-
ducing selectable markers in the repair vector to isolate
target clones persisted in order to make the correction
task feasible. Even if targeted correction has been
achieved in loci which are not being expressed [5],
genes which are highly expressed are expectedly edited
at higher frequencies [6, 7] due to the more accessible
state of their chromatin.
Gene edition with recombinant nucleases follows a
multi-step procedure mainly divided into three sec-
tions: 1) creating specific double strand breaks (DSBs)
by engineered nucleases, near to the desired locus on
the genome; 2) triggering the homology-directed repair
(HDR) process and editing the gene by means of adding
a donor vector with homology arms and selectable
markers as a repair template for homologous recombin-
ation; and 3) seamlessly removing selectable markers
from isolated clonal or semiclonal populations. Repair
template contains homology arms matching 5’ and 3’
regions surrounding the DSB point. Selectable markers
are needed to identify successfully corrected genomes.
The rationale behind this repair has been highly argued* Correspondence: telomerasi@yahoo.es
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and readers are referred to the literature for a detailed
explanation [8].
At present, there are three major kind of engineered nu-
cleases: zinc finger nucleases (ZFNs), transcription
activator-like effector nucleases (TALENs), and clustered
regularly interspaced short palindromic repeats/associated
(CRISPr/Cas) nucleases [9]. All these nucleases contain an
encoded recognition mechanism and a nuclease (Fok I or
Cas9). TALENS have been reported to be more efficient
than ZFNs [10], and generation of off-target mutations by
TALENs have also been found to be fewer [11]. The con-
struction of guide RNAs in CRISPr/Cas nucleases has
been developed to a simple and efficient procedure [12]
but lacks the heterodimerization safety mechanism shared
by ZFNs and TALENS [13], which implies the recognition
of two different targets in order to promote a DSB event.
Elimination of the selectable markers after genetic re-
pair with most common Cre/loxP, Flp/FRT, and ϕC31
integrase/attP-attB recombination systems leave small
ectopic sequences in the genome, which even if located
in intronic regions could have the potential to interfere
with transcriptional regulatory elements [14], splicing
machinery, or cause unexpected translocations and gen-
ome reorganizations [15].
The addition of transposons/transposase as an alterna-
tive to the list of recombinase mechanisms [16] has con-
stituted a second milestone after the engineered nucleases
for completing genome edition in a seamless manner.
Transposons are well known to work in mammalian cells
and transposases produce safer elimination of the select-
able cassettes without altering genomic DNA sequence.
PiggyBac transposon has been proven to efficiently trans-
pose in mammalian cells including hES cells [17, 18]. The
strategy of introducing a double selectable marker gene
(puroΔtk) in a transposon in the repair vector was devel-
oped previously and applied to the correction of A1AT
deficiency in patient-specific iPS cells [19]. After hom-
ologous recombination, transposase is transgenically
expressed and carries out the excision of the selectable
cassette from the repaired clones by recombination be-
tween head and tail (PB) sequences. The excision over-
rides a TTAA motif—AA from the transposon head
and TT from the transposon tail—which leaves an in-
tact genome if it has been integrated at a TTAA site as
is the case in our work. Interestingly, the hyperactive
transposase has double efficiency for excision rather
than for integration, which is a convenient trait and an-
other reason for having chosen this system for cystic fi-
brosis transmembrane conductance regulator (CFTR)
gene repair [20].
Cystic fibrosis (CF) is one of the most frequent rare
diseases, caused by mutations in the CFTR gene. Apart
from symptomatic treatments, there is no alternative to
cure the disease at present [21]. Recently, the correction
of the pF508del mutation in patient-specific iPS cells
has been published [22, 23], and confirmation of the
production of the wild-type protein by the corrected
cells has been performed after directed differentiation
to intestinal epithelial cells. In our case, the differenti-
ation of pluripotent repaired cells to airway and intes-
tinal epithelial cells has been performed to confirm
functional restoration of the CFTR channel and data
will be published elsewhere as it is beyond the scope of
this method of genetic correction by TALEN-edited
homologous recombination.
In the present work, we designed and constructed a
PiggyBac-based HR vector, and nucleofected it in com-
bination with TALENs specifically designed to cut in the
region near the CTT (pF508del) deletion of the human
CFTR gene. Positive selection of the recombinant clones
was performed by resistance to puromycin, and poly-
merase chain reactions (PCRs) designed to detect the
integration of vector homology arms were conducted
on genomic DNA from all of them. Hyperactive trans-
posase was transfected in a list of more than ten posi-
tively targeted clones, and upon transposon removal a
negative selection for Tk expression was conducted by
treatment with fialuridine (1-(2-deoxy-2-fluoro-1-D-
arabinofuranosyl)-5-iodouracil; FIAU), an analog of
ganciclovir. Surviving clones were expanded and
checked by PCR for elimination of the selectable cas-
sette, and CFTR alleles were cloned and sequenced on
several of them to identify successfully repaired patient-
specific CFTRpMC3.1/pF508Δ. One hIPS cell line from
each of two patients was corrected. CF is a monogenic
recessive disease, therefore heterocygotic correction is
sufficient to restore CFTR function in repaired cells.
Methods
There are seven major stages in the correction of
disease-associated genetic mutations by TALEN-edited
seamless HR in patient-specific pluripotent cells: 1) the
generation of patient-specific iPS cells including con-
firmation of the mutation and its homo- or heterocygo-
sis; 2) the design and construction of the nuclease and
the donor vectors for HR; 3) the repair experiment it-
self with selected nucleases according to their cutting
efficiency and the preparation of replicated cultures of
positively selected populations; 4) the design and carrying
out of the PCR screening to assess positive candidates; 5)
the elimination by transposition of the selectable double
marker in chosen candidate populations and negative se-
lection procedure; 6) the cell cloning and screening of se-
lected populations for the effective elimination of the
selection cassette; and 7) the confirmation of the bona fide
correction and the absence of other unwanted genetic
modifications in chosen repaired clones.
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Patient-specific hIPS cell line establishment and
characterization has been performed according to the
work already described elsewhere [24, 25]. In this
method, we describe stages 2 to 7 of the genetic correction
of pF508Δ mutation in two of the reprogrammed hIPS
lines. Methodology for completion of each step is detailed
in the following sections.
Design and construction of the donor/targeting vector
ZFN expression vectors were originally designed using
ZiFiT targeter software provided by the Zinc Finger Con-
sortium (http://zifit.partners.org). CompoZr® Knockout
ZFN, engineered ZFNs for pF508Δ targeting from Sigma™,
were supplied under a collaboration agreement. TALEN
vectors designed to cut in the same spot as ZFNs were de-
signed and purchased from Transposagen®.
pMC3.1 donor vector was designed as a unique se-
quence and synthesized. Two homology arms of 916
base pairs upstream and downstream of the DSB spot
were included, respectively, with five silent point muta-
tions at the 3’ side of the 5’ homology arm designed in
order to: a) create a restriction site (for BglII as it has
unique cutting site in the whole recombination region)
which will be useful in the identification of the recom-
bined alleles during screening; b) avoid recognition of
the recombined allele for the nucleases (re-targeting);
and c) design specific primers for the recombined allele
versus the endogenous ones. Besides the homology arms,
the synthetic (control) vector designated as Seq_1 con-
tained homology arms surrounded at 5’ and 3’ ends by
specific genomic regions chosen as primers for PCR de-
tection of recombination events, respectively. EcoRI and
MluI sites were designed at both ends of each string,
respectively, so they could be easily eliminated from the
control vector during construction of the targeting
vector.
Construction of the donor vector for HR experiments
was thus performed in three steps of modification of this
synthetic control vector: first, EcoRI digestion of Seq_1
eliminated the contiguous genomic region in the 5’ arm
(generating Seq_2); then MluI digestion eliminated the
contiguous genomic region in the 3’ arm (Seq_3); in the
third step, digestion of the NheI/NotI fragment from the
pMCS-AAT-PB:PGKpuroΔtk vector was cloned into
NheI/NotI sites in Seq_3, introducing the PuroΔtk/
PiggyBac (PB) transposon cassette in between the hom-
ology arms to generate the donor targeting vector
pMC3.1 (Seq_4). PMCS-AAT-PB: PGKpuroΔtk is the
targeting vector used for A1AT correction [19] and was
obtained from the Sanger Institute (http://www.sanger.
ac.uk/form/-C3ZIws9wQ4CSysnb1AY4kA) under an
MTA agreement.
The pMC3.1 targeting vector, besides having a strong
double selection cassette, allows for screening strategies
for each step of the HR procedure: PCR amplification
for positive recombinant clones, restriction fragment
analysis of the recombinant allele to check the stability
of its open reading frame (ORF), and detection of the
reverted allele after excision of the transposon/selection
cassette, when we can use the point mutations located
at the nuclease recognition sites to amplify specifically
recombined and non-recombined (either mutated or
corrected) alleles. This screening system shares a com-
mon forward primer and uses two different reverse
primers which will recognize native from recombined
alleles.
Nuclease efficiency assessment
CelI assay [26, 27] for detection of mutations was used
to estimate the cutting efficiency of ZFN and TALEN
nucleases used in this work. The rationale behind this
method of detection of nuclease activity is the gener-
ation of mismatches in the genomic DNA as a conse-
quence of natural cellular repair of a DSB in the
absence of homology templates. This mechanism of re-
pair is known as non-homologous end-joining (NHEJ)
and the celery enzyme CelI was found to cut dsDNA at
mismatches but not at paired bases. After PCR amplifi-
cation of the fragment, digestion confirms the presence
of repaired DNA at that site, which implies previous
DSB generation and repair by NHEJ. Surveyor assay
kit® from Transgenomic® was used following the manu-
facturer’s instructions. Briefly, K562 and CFhIPS3.18
were nucleofected with 2 μg of each nuclease plasmid
and cells were cultured for 48 hours. Genomic DNA
was extracted, digested, and run on agarose gels. Results
were obtained by densitometric quantification of digested
versus undigested bands, using the formula 100 × cleaved/
cleaved + parental.
Cell culture and characterization
hIPS cell lines were generated and described elsewhere
[26]. Briefly, CFhIPS3.18 and CFhIPS4.4 were cultured
on human foreskin fibroblasts, HFF-1 feeder layers with
HESNEW_S media containing KO DMEM supple-
mented with 20 % knockout serum replacement, 1 mM
GlutaMax, 0.1 mM 2-mercaptoethanol (2-ME), 1× non-
essential amino acid and 8 ng/ml of fibroblast growth
factor 2 (FGF2). All cultures were performed without
the addition of antibiotics. Subculture was performed
mechanically for up to eight passages during line deriv-
ation, and then recombinant trypsin was used in com-
bination with ROCK inhibitor to produce near-single
cell suspensions (i.e., small clumps of 5–20 cells, approxi-
mately). Established pluripotent lines were characterized
for stemness, pluripotency and genetic stability during
continuous expansion in culture following basic protocols
with slight modifications as described previously [28].
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Stem cell markers were detected by immunofluorescence
in pluripotent colonies, and pluripotency markers were
detected after spontaneous differentiation of embryoid
bodies (EBs) for 10–12 days in suspension cultures on
SBF-containing medium, previously to continuous 25–30
days in adherent cultures in the same medium. Instead of
in vivo differentiation by teratoma formation, a novel
method of three-dimensional culture of EBs was assayed
on Aggrewell® plates. After a month of continuous culture,
mature EBs were paraffin-embedded and sectioned for im-
munohistochemistry staining following a standard proced-
ure. One line from each patient was chosen to perform
homologous recombination experiments.
Gene targeting in CFhIPS lines
CFhIPS3.18 and CFhIPS4.4 were nucleofected with
ZFN and pMC3.1 plasmids at a ratio of 1 μg of each
ZFN and 2 μg of the targeting vector per million cells.
For TALEN experiments, TALENs and donor vector
were mixed and nucleofected at a ratio of 2 μg of each
circular vector per million cells using an Amaxa
nucleofector device II and following manufacturer in-
structions. After nucleofection, hIPS cells were seeded
onto HFF-1/W3R feeders [29], kindly provided by Dr
Chen at the Johns Hopkins University School of Medi-
cine in Baltimore, MD, USA. These cells are resistant
to neomycin, hygromicin and puromycin, allowing se-
lection for the expression of the PuroΔtk cassette.
Briefly, subconfluent cells were trypsinized and resus-
pended in HESNEW medium containing ROCK inhibi-
tor before centrifugation at 200 g and resuspension in
nucleofector solution 2 (and lately equivalent P3 due
to commercial availability). B16 program was used for
best results combining nucleofection efficiency and cell
viability. Nucleofected cells were plated onto resistant
feeders described before in the presence of ROCK in-
hibitor for 1 day in HESNEW_S, and thereafter the
media was substituted by the puromycin-containing
HESNEW_R at 1 μg/ml. Emerging resistant clones
were allowed to grow and subcultured individually up
to 16 days after plating, feeding them every second
day. Grown colonies were manually picked and trans-
ferred to 48 tissue culture microplates, which were
grown for an additional 5 to 8 days. Clones were then
replicated by trypsinization, and grown until at least
50 % confluence. One replica plate was frozen and the
other was used for genomic DNA extraction which
was performed manually by a basic protocol. Briefly,
cells were lysed in high salt content buffer and gen-
omic DNA was precipitated with isopropanol and
washed in ethanol before resuspension in Tris-EDTA
buffer.
PCR screening and Sanger sequencing
Genomic DNA from 48-well replica plates of colonies re-
sistant to puromycin was extracted by proteinase K diges-
tion of the cells on the plate by lysis buffer and
precipitation of the DNA with isopropanol after transfer-
ring lysates to eppendorf tubes. DNA pellets were washed
in 70 % ethanol and resuspended in Tris-EDTA buffer.
PCRs were performed at annealing temperatures accord-
ing to temperature gradient optimization for each pair of
primers, and extension times according to product length
(see Table 1). Table 2 shows detail of the chemistry of the
PCRs according to product length. Genotyping PCRs were
performed for both recombination arms. Primers for amp-
lification of the homology arms were located in the gen-
omic region (5’ on the 5’ arm and 3’ on the 3’ arm,
respectively. PCR screening for both arms plus BglII di-
gestion pattern were used to assign positive clones for
homologous recombination (Fig. 1 depicts the scheme of
the repair strategy). Primers used for each step of the
screening are indicated as arrowheads in Fig. 1 and their
sequences are listed in Table 3.
After correction, two rounds of PCR were performed
to confirm the absence of reintegration of the PiggyBac
double selectable marker cassette. First, Recomb F/ZFN
R primers were used to check for correct size of the tar-
geted fragment after cassette excision in the edited allele
(i.e., in the original place), and then Reint primers were
used to confirm that no random reintegration of the
transposon occurred in the genome.
Transposon excision in CFhIPS/ pMC3.1 sub-lines
Confirmed positive clones for HR were thawed and ex-
panded, and subjected to cassette excision by nucleofection
of 5 ug of the pCMV-HAhyPBase vector that encodes the
transposase per million cells. FIAU selection was applied
from day 1 onwards after nucleofection, and resistant
clones were mechanically split and subcultured for at least
three passages until genomic DNA was extracted for ana-
lysis. After FIAU selection for Tk negative events resulting










95 5’ 95 5’ 95 5’
95 30” 95 30” 95 30”
64 15” 64 45” 64 45”
72 30” 72 2’ 72 3’
40 cycles 40 cycles 40 cycles
72 7’ 72 7’ 72 15’
bp Base pair, DSB Double strand break, PCR Polymerase chain reaction. Left
numbers on each cell of the table correspond to Temperatures, and right
numbers correspond to times for each step of the PCR amplification
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from the elimination of the selectable cassette, resistant col-
onies were isolated and duplicated in P48 well plates. One
replica was expanded in culture while the other was used
for PCR screening and DNA sequencing. CFTR alleles were
cloned and sequenced in both senses with 5’ and 3’ primers
separately, and reactions were purified with a column and
sent to Secugen®. Results were visualized in Chromas soft-
ware and browsed in GenBank for identity check.
PROGNOS and array comparative genome hybridization
Stage 7 of DNA repair, which is confirmation that no other
mutations have been generated during the repair proced-
ure, was completed by PROGNOS software and Sanger se-
quencing of the predicted off-target sites. Predicted Report
Of Genome-wide Nuclease Off-target Sites (PROGNOS)
online software from Gang Bao laboratory was used to
evaluate potential rearrangements in off-target sequences
throughout the genome after pF508Δ correction by HR
[30]. Target sequences for both TALENs, variable length of
the spacer from 10 to 30 bases, and precise repeat variable
domains (RVDs) of the TALENs were used to interrogate
PROGNOS for possible off-target sequences. Genomic
DNA extracted from corrected clones was used as a tem-
plate for PCR amplification of predicted off-target loci with
primers designed by the same software. Sanger sequencing
of the products was performed to check for the absence of
mutations which would have been expected as a result of
NHEJ events after putative unspecific cut by TALENs.
The same genomic DNA from corrected lines was
submitted to comparative genome hybridization array
(aCGH) analysis (outsourced).
Results and discussion
Generation and characterization of patient-specific hIPS
cell lines
A panel of ten hIPS lines was established from keratino-
cytes and fibroblasts of two CF patients and one healthy
donor (in preparation). Stable pluripotent lines were
continuously cultured and expanded to prepare frozen
stocks at low passages (6–15). Additional file 1 (Figure
S1) and Additional file 2 (Figure S2) show representative
results of the immunofluorescence for stemness and
pluripotency markers in several of the lines analyzed
from each patient. Genetic stability was assessed by
karyotype every ten passages, and was found to be nor-
mal in all ten lines tested up to passage 42. Additional
file 3 (Figure S3) shows the karyotype of hIPS3.18 and
hIPS4.4 at the same passage that was used for the HR
experiment. Tissue formation from all three germ layers
was assessed by hematoxylin and eosin staining in sec-
tions of paraffin-embedded EBs cultured for more than a
month, following a novel protocol whose results are
equivalent to teratoma formation in mouse models
(Additional file 4: Figure S4).
Basic human pluripotent culture is best routinely
maintained in parental HFF-1 fibroblasts which are ir-
radiated at 40 Gy and frozen as batches of around 180
million cells each in vials of 2–3 million cells each.
Growth and amplification of resistant populations is
then best achieved using resistant human fibroblasts,
which are robust feeders during the relatively long
period of culture for clonal growth of rare events, as
positive recombinants. With this system, feeder supple-
mentation is avoided at any time and pluripotent cul-
ture is robustly supported.
TALEN cutting efficiency
Efficiency of CompoZr® CFTR_ZFN was calculated to be
12.4 % by Sigma in the K562 human promyelocytic
leukemia cell line. Surveyor assay for TALENs resulted
in a cutting efficiency of 2.76 % in one of our CFhIPS
pluripotent cell line (see Additional file 5: Figure S5 for
an image of electrophoresis results of Surveyor assay in
oneCFhIPS line). This discrepancy and lower cutting
efficiency for TALENs could be attributable to the differ-
ences in efficiency of nucleofection between the two cell
types which are widely known. Nucleofection efficiency
Table 2 PCR reaction chemistry
SHORT PCR MED/LONG PCR
Working dil Final conc./rxn μl/25 μl Final conc./rxn μl/25 μl
DNA seq-1 696.9 ng/μl 10−3/10−6 ≈300 ng 2.0 μl ≈300 ng 2.0 μl
Primer up 10 μM 0.4 μM 1.0 μl 0.4 μM 1.0 μl
Primer dwn 10 μM 0.4 μM 1.0 μl 0.4 μM 1.0 μl
dNTPs 2.5 mM 100 μM 1.0 μl 200 μM 2.0 μl
Buffer 10× 10× 1× 2.5 μl 1× 2.5 μl
MgCl2 50 mM 3 mM 1.50 μl 2 mM 1.0 μl
Taq 5 U/μl 2.5 U 0.5 μl 0.5/1/2.5 U 0.5 μl
H2O 15.5 15
PCR Polymerase chain reaction; dil dilution; conc concentration; rxn reaction; dNTPs deoxynucleotides triphosphates mixture; dwn down (3' end)
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in human pluripotent stem cells is known to be signifi-
cantly lower than in mouse pluripotent stem cell lines
and in other cell types in general.
Correction of pF508Δ in patient-specific hIPS cell lines
Fibroblasts from two CF patients were reprogrammed to
pluripotency by viral-driven expression of the four
Yamanaka factors. Homocygous pF508 deletion was con-
firmed by digestion PCR as previously published [31],
and Sanger sequencing, in both original fibroblasts and
resulting pluripotent lines. From a panel of derived lines,
CFhIPS3.18 and CFhIPS4.4 from each patient, respect-
ively, were nucleofected with a pair of TALEN and a
donor vector designed to introduce a CTT to restore
pF508Δ mutation. Figure 1a shows the diagram of the
strategy for correction of the mutation. The original mu-
tated allele in exon 11 of CFTR would be cut by ZFN or
TALEN recombinant nucleases in the presence of the
Fig. 1 a Schematic drawing of the genomic edition and HR steps to correct pF508del mutation. After specific cut by ZFNs or TALENs, repair
vector is used as a template for homologous recombination and the process generates the P allele, which shows homology arms and position of
the primers (P3–4 and P5–6) used for their amplification and detection, with one primer 5’ or 3’ in the genomic region and the other 3’ or 5’ in
the terminal repeats of the transposon cassette, respectively. Transposase is then expressed in target cells to eliminate the double selectable
marker, which has sequentially selected cells resistant to puromycin which have integrated the donor vector and, from these, cells resistant to
Fialuridine which have eliminated the transposon containing the modified Thymidine kinase gene in sequential steps. Primers P1–2 allow for
confirmation of the repaired sequence. b Genomic sequence detail of the targeting region, showing the position of the pF508del mutation, ZFN
and TALEN target sequences and spacers, silent mutations introduced to avoid retargeting and to create a restriction site to distinguish targeted
allele, and TTAA position for the introduction of the PiggyBac double selectable marker. TALEN Transcription activator-like effector nuclease, ZFN
Transcription activator-like effector nuclease
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targeting vector, which would have generated the P allele
by homologous recombination. A transposon vector con-
taining the double selectable marker PuroΔtk was chosen
for the possibility of seamless excision of the cassette after
correction. After assignation of positive targeted clones by
PCR using primers depicted as arrows in the diagram,
nucleofection of the hyperactive transposase would restore
genomic sequence to the corrected/edited one. Silent mu-
tations created a BglII site in the left homology arm to aid
in the identification of the edited allele. Additional silent
mutations were introduced in the targeting vector in the
recognition sites for ZFNs and TALENs to avoid retarget-
ing as well, as indicated in Fig. 1b. The indicated TTAA
marks the position of integration of the transposon. A
ZFN and a TALEN pair of recombinant nucleases were
designed to target the same locus, and homologous re-
combination experiments were performed with both using
the same targeting vector with a transposon-based double
selectable marker. Under continuous puromycin selection,
1318 resistant clones were screened by PCRs for 5’ and 3’
arms respectively after nucleofection of ZFNs + pMC3.1
vectors into the CFhIPS3.18 line, with no positive result
for a recombination event. ZFN vectors targeting the same
region had been used before with similar results of no
demonstrated correction [32].
Efficiencies of recombination for the pMC3.1 repair vec-
tor in combination with TALEN plasmids are shown in
Table 4 for two CFhIPS lines, each one corresponding to
each donor patient studied. Figure 2a and b shows exam-
ples of PCR results for detection of 5’ and 3’ homology
arms, respectively. Digestion with BglII was performed on
an aliquot of 5’-arm PCR to confirm the recombinant P al-
lele origin of the amplified DNA (Fig. 2c), and resulted in
the first indication that correction occurred only in one al-
lele by the uncut band. Selected positive clones were
nucleofected with HAHypBase vector to eliminate the
PiggyBac transposon with the double selectable marker
cassette. Resistant populations to FIAU were isolated and
cloned, and PCR screening was performed to confirm posi-
tive events of elimination of the selectable marker (Fig. 2d),
completing the correction of the pF508Δ mutation in re-
spective hIPS lines from the two patients assayed.
After confirming correction and elimination of the se-
lection cassette from the designated clones, DNA se-
quencing was performed on the full recombination
region on cloned alleles to confirm positive correction/
addition of the CTT to the original mutated sequence in
heterozygosis, and absence of additional mutations in
the region. Figure 3 shows lack of CTT on one of the
cell lines corrected (Fig. 3a) and CTT addition on Sanger
sequencing electropherogram of genomic DNA after edi-
ted repair (Fig. 3b). In Fig. 4, fragments of the edited/
corrected alleles in both lines are annotated. CTT pres-
ence along with Bgl-II introduction and silent mutations
are indicated. Full sequences in Additional files 3 and 4
contain the sequencing pattern and alignments of the
full homology fragments after repair in both lines
assayed. Correction of the mutation resulted in hetero-
cygosis in all sub-lines analyzed.
Table 3 Sequences of primers used in each step of screening
for positive and negative selection steps during edited genome
repair
CR4 Up TAG GTT GTA GCA GTG GTA GTG
CR4 Down CTC TAT GTA ACT CTT GTC TCT TCC
ZFN F TGG AGC CTT CAG AGG GTA AA
ZFN R TTT CAT GTG TTT GCA AGC TTC T
Integra5.1up TCC TCT GCT ACC TCC TTT CCT TCT
Integra5.2up TCT TCC TCT GCT ACC TCC TTT CCT
Integra5.3up TGC TTT TTC TTC CTC TGC TAC CTC C
Integra5.4up TTC CTC TGC TAC CTC CTT TCC TTC T
Integra5.5up TCC TCT GCT ACC TCC TTT CCT TC
Integra5.1dn GGA GCT CCA AGC GGC GAC TG
Integra5.2dn GCC TCA CGG GAG CTC CAA GC
Integra5.3dn TGA CAA GCA CGC CTC ACG GG
Integra5.4dn CTC ACG GGA GCT CCA AGC GG
Integra5.5dn ACC GCA TTG ACA AGC ACG CC
Integra3.1up ACA GAC CGA TAA AAC ACA TGC GTC A
Integra3.2up CAG ACC GATA AAA CAC ATG CGT CA
Integra3.3up AGA CCG ATA AAA CAC ATG CGT CA
Integra3.4up CAG ACC GAT AAA ACA CAT GCG TCA A
Integra3.5up AGA CCG ATA AAA CAC ATG CGT CAA
Integra3.1dn AGG CAC CTT CCG CAA CTT TTC CA
Integra3.2dn GGC ACC TTC CGC AAC TTT TCC A
Integra3.3dn AGG CAC CTT CCG CAA CTT TTC C
Integra3.4dn GGC ACC TTC CGC AAC TTT TCC AC
Integra3.5dn GGC ACC TTC CGC AAC TTT TCC
Reint F CTG CTG CAA CTT ACC TCC GGG ATG
Reint R CCA ATC CTC CCC CTT GCT GTC CTG














CFhIPS3.18 122 × 106 648 60 9.26 % 4.9 × 10−5
CFhIPS4.4 58 × 106 98 10 10.20 % 1.7 × 10−5
PCR Polymerase chain reaction
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Off-target analysis and aCGH
After confirming correction of the mutation by Sanger
sequencing, PROGNOS software was used to predict off-
target sequences of the nucleases throughout the genome.
PROGNOS results are summarized in Table 5. Mis-
matches required for off-target cut by the TALEN pair
used in this work are detailed in column 3, for the 5’
TALEN or for both. PCR primers given by PROGNOS
for all 15 off-target sites are listed in Table 6. Genomic
DNAs from repaired and sequenced clones included in
Fig. 4 were used for sequencing of the PCR amplicons
suggested by PROGNOS, with the result of wild-type
sequences in each case (in preparation, data not shown).
Comparative genome hybridization between parental and
edited lines resulted in no relevant genomic alterations
due to the TALEN-edited targeted correction of pF508Δ
(in preparation).
Conclusions
It is well established that a feeder-based culture is better
than feeder-free culture methods to maintain karyotypic
stability on human pluripotent stem cells [33]. The pres-
ently described culture system is designed to avoid xeno-
biotics as much as possible whilst maintaining basic
culture conditions for pluripotent cells, i.e., a feeder-based
cell culture system, which is known to maintain genomic
stability for a larger number of passages compared to
feeder-free systems [34]. The use of human parental and
human resistant feeder sub-lines allowed for robust cul-
tures which were easily scalable and frozen/thawed, add-
ing versatility to the technology and, overall, posing less
stress to cells in terms of genomic stability. The HFF-1
human foreskin fibroblast line from ATCC and the HFF-
1/W3R Wnt expressing sub-line have proven robust tools
in the design of the culture protocol for the different steps
of the procedure. HFF-1/W3R is resistant to neomycin,
hygromycin and puromycin. Moreover, the use of con-
tinuous lines as feeders as opposed to traditional pri-
mary mouse embryonic fibroblasts adds reproducibility
and reduces workload. In conclusion, the method
chosen in this protocol with the use of parental human
foreskin fibroblasts and resistant sub-lines for homologous
Fig. 2 PCR screening steps for detection of pF508 correction. a Ethidium bromide stain of the gel showing positive amplification of the left homology
arm of the targeted P allele. b In a similar fashion, gel image showing positive clones for amplification of the right arm. In both a and b, positive PCR
reactions correspond to PCRs performed with same test primers on the control vector as a template, which contains adjacent genomic sequences to
the 5’ end of the 5’ arm and the 3’ end of the 3’ arm. c BglII cut of the 5’ arm, confirming the presence of P recombined allele on positive
clones. d PCR result of the targeted region after elimination of the selection cassette by transposase expression. Band size confirms
elimination of the transposon-based double selectable marker from the homologous integration site
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recombination experiments has proven robust and has
allowed the achievement of genetic correction in about
2 months, a shorter period compared to other protocols
[19].
In previous HR strategies, the removal of the selection
cassettes left residual sequences in the edited locus,
which although placed more often in the intron part of
the edited gene implied locus restrictions for HR strat-
egies. The new strategy using transposon/transposase as
the recombination method avoids the introduction of
foreign sequences in the recombinant allele. Further-
more, the pMC3.1 vector, apart from having a strong
+ (puro)/–(Δtk) PB selection cassette, offers three differ-
ent screening strategies. The first one is a PCR amplifi-
cation of each recombined homology arm that only will
be positive once the recombination is achieved. In these
PCRs, clones that are positive for 5´ and 3´ hybrid se-
quences were detected. The second screening implies
the digestion of the 5’ arm with Bgl-II and their sequen-
cing, in order to check the stability of the CFTR ORF.
The third screening step was performed after cassette
excision, where silent mutations introduced to avoid nu-
clease retargeting after correction were used to design a
three-primer PCR system that will amplify distinctively
the non-recombined alleles (wild-type (wt) used as a
PCR-positive control and pF508Δ) from the recombined
allele. This screening system shared a common forward
primer and was based in two different reverse primers
that recognized and amplified the native CFTR/
CFTRpF508Δ (wt/mutated) allele or the recombinant
CFTR/pMC3.1 (wt/edited) allele.
The use of TALEN-mediated HR in combination with
a transposon-based double selectable marker achieved
Fig. 4 Annotated DNA sequences of the edited alleles in both corrected CFhIPS lines. Annotated sequences of edited alleles in a CFhIPS3.18 and
b CFhIPS4.4. The BglII site created de novo and the rest of silent mutations introduced to avoid nuclease retargeting are indicated in the panels
Fig. 3 Sanger sequencing on negatively selected clones after
correction of pF508del mutation. a Representative genomic
electropherogram of CFhIPS3.18, showing the point of the
deletion. b Genomic sequence electropherogram after
homologous recombination and marker transposition, showing
CTT addition which means correction of the deletion causing CF
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correction of pF508Δ mutation in hIPS lines from two
patients at efficiencies ranging 1.7-4.9 x 10−5, resulting
in a feasible protocol in terms of both workload and
timing. Raw data corresponding to the homologous re-
combination experiments was communicated at a sym-
posium organized by the Spanish Society of Gene and
Cell Therapy, and is available online at http://www.
setgyc.es/home/ZFN_3_M_Camarasa.pdf.
Development of generations of hIPS cells towards clin-
ical production have been reviewed [35]. The present
method improves previous endogenous genetic correc-
tions performed in patient-derived stem cells in the fol-
lowing aspects: a) pluripotent cell culture is performed
with minimal xenobiotic components and without the
addition to antimicrobe antibiotics; b) correction is per-
formed in a feeder-based cell culture system, which is
known to offer more robustness and stability; c) repair
vector has been designed as a transposon with a double
selectable marker, which facilitates the processes of selec-
tion and seamless elimination of the selection cassette;
Table 6 Primers inferred by PROGNOS algorithm for TALEN pair off-target check
R. S. Forward_Primer Reverse_Primer
1 98 GGCAAGTGAATCCTGAGCGTG CATTCACAGTAGCTTACCCATAGAGGAAAC
2 37 CTGTCAAAGTGGGCTCCTATTTGC CAGACATGTCAAAAAGATGCTGCCCAGA
3 26 GGGTAGCAGCGAAACAGAAAAGG GGCAACACAGTGAGACTCCATC
4 17 CTGCTCCATTGGCCTATATCTCTG CAAACTGACTCCAGTGAGATGGTG
5 26 CTTTTGGTGGCGAAATAGGGGTG CTTATGCATGCGCACCCATGTAC
6 17 GAAGATAGGGAACACCTACTGACAAGTCAT CCTTCCACTGTTTCTTTCCTATATTCTTGTCC
7 25 GGAAAGACAGTAGTCATCTCCCC CCAGGACATGTCTGAGGAGTCT
8 17 GCCTAAATCCAACATTATACTAGATGTCCC GATCTGCATGCTGCTTCTGCC
9 18 GGAGCATGGTTGCTGGATCATAC CACAGGCTGCTCTTGCAAAAACAC
10 17 CCTGGCTGCCTCTTTGACTG GCCACTTTCCTGAGAAGAACTGC
11 26 GGATGTGGCTCCTGGGTTTTTAG GTAACCACATGCCTAGAGGGTAGT
12 17 CATGAGTCTCCAGACTGTACCTTG CACTCCTTTCAGGTGTGTGTTGC
13 18 GGCACCAAGAACATACAACAGGG GCTGTGGAGTTGTGTGAGCTCT
14 17 AGCATAGCACTGGAAGCTCTAGCC CCTCTGGACACAAATCCAGTCAGT
15 20 GGAGCTGGTGTCACTGCAGA GACTGCCCAAAATCAAGCGTGGT
16 13 GGAGCTACAGTTAGGGTGCAATTC GTTGCCAGAAGGCAGAATTAGGAG
Table 5 PROGNOS results for prediction of pF508del_TALENs off-targets
Ranking Hom. Mismatches Chromosome_Name Genomic_Region Closest_Gene
1 98 0_0 chr7 Exon CFTR
2 37 6_1 chr4 Intergenic TECRL
3 26 6_2 chr9 Intron PALM2-AKAP2
4 17 6_3 chr19 Intergenic ZNF714
5 26 6_2 chr17 Intergenic NLRP1
6 17 6_3 chr13 Intergenic LINC00550
7 25 4_3 chr9 Intron MPDZ
8 17 6_3 chr2 Intergenic KCNE4
9 18 4_4 chr9 Intergenic MAMDC2
10 17 6_3 chr8 Intergenic FGF20
11 26 6_2 chr6 Intergenic KIAA1009
12 17 6_3 chr6 Intron CDKAL1
13 18 4_4 chr3 Intergenic TMEM207
14 17 6_3 chr13 Intron ATP11A
15 20 5_3 chr8 Intergenic WRN
16 13 5_4 chr4 Intergenic PDHA2
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and d) PCR screening has been designed to discern the
endogenous from the modified allele, both either wild-
type or mutated. Overall, the method described allows
correction of patient-specific induced pluripotent cells in
less than 3 months, and corrected cells have been directly
cultured in a format which allows rapid scaling up for
downstream applications.
Additional files
Additional file 1: Immunofluorescence detection of stem cell
markers in CFhIPS cell lines. Immunostaining for stem cell markers in
ten of the 49 lines originally generated. Markers are indicated in the
panel and are distributed in columns. Lines 1 to 10 from top to bottom
are designated in the panel as well. From ten lines analyzed, one
presented a chromosomal anomaly and its name is depicted in red.
(TIF 856 kb)
Additional file 2: Immunofluorescence detection of pluripotency
markers in ten CFhIPS cell lines. Ectoderm (nestin, Tuj-1), mesoderm
(eomes, A-actinin) and endoderm (Sox 17, GATA4) markers are shown in
the ten lines fully characterized for this project. (TIF 757 kb)
Additional file 3: Karyotypes of CFhIPS cell lines corrected for
pF508del. G-bands of CFhIPS3.18 and CFhIPS4.4, respectively, as indi-
cated in the panels. Both lines are karyotypically normal. (TIF 1037 kb)
Additional file 4: Histological stain for in vivo pluripotency
assessment. Mallory’s tetrachromic staining of paraffin embedded
embryoid bodies (EBs) derived from CFhIPS3.18. (A) Different types of
tissues could be found in the EBs including (B) columnar epithelium
(endoderm), (C) cartilage (mesoderm) and (D) cuboidal and squamous
stratified epithelium (Ectoderm). Scale bars: A, 100 μm; B–D, 50 μm.
(TIF 521 kb)
Additional file 5: Surveyor mutation detection assay to estimate
TALEN cutting efficiency. The full homology arm containing the cutting
sequence was amplified and digested with CelI and T7 endonucleases as
indicated in the panel. Expected size of digested bands after cut is
indicated to the right and restriction fragment size marker bands are
indicated to the left. Densitometric analysis of the image resulted in an
indel frequency of 2.76 %. (TIF 1104 kb)
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